What does Desh Rakshak do?

Desh Rakshak Aushdhalaya Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on Ayurvedic and herbal products. As of March 2025, it reported net sales of 4 Cr and a market cap of Rs 17 Cr.

Overview:<BR>Desh Rakshak Aushdhalaya Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of pure Ayurvedic and herbal products.<BR><BR>History:<BR>The company was originally established in 1901 as a proprietorship by Shri Bhagwant Rai Jain and was converted into a Private Limited Company in July 1994. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 17.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.34 <BR>Return on Equity: 5.37% <BR>Price to Book: 1.78 <BR><BR>Contact Details:<BR>Address: Bhagwant Kuti, Kankhal Haridwar UTT : 249408 <BR>Phone: 91-1334-243833 <BR>Email: daral96@yahoo.in/dral95@yahoo.com <BR>Website: http://www.deshrakshak.com

Has Desh Rakshak declared dividend?

No Dividend History Available

What is the technical trend for Desh Rakshak?

As of May 29, 2025, Desh Rakshak's technical trend is mildly bullish, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

As of 29 May 2025, the technical trend for Desh Rakshak has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some weakness in the short term. Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, supporting the overall mildly bullish trend. Daily moving averages are bullish, reinforcing the positive outlook. The KST indicates a mildly bearish trend on the weekly, but bullish on the monthly, which adds mixed signals. Dow Theory shows a mildly bearish trend on the weekly, with no trend on the monthly. Overall, the technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

Who are the peers of the Desh Rakshak?

Peers of Desh Rakshak include Genesis IBRC, Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, Chemo Pharma Lab, and Parmax Pharma. Desh Rakshak has the highest 1-year return at 415.29%, while most peers exhibit Below Average management risk and growth, with Vineet Laborator showing the lowest return at -49.62%.

Peers: The peers of Desh Rakshak are Genesis IBRC, Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, Chemo Pharma Lab, and Parmax Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at none, while Average management risk is found at Vineet Laborator, and the rest have Below Average management risk. Growth is Below Average for Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, and Parmax Pharma, while Desh Rakshak also falls into the Below Average category. Capital Structure shows Good ratings at Ishita Drugs, Zenith Health, and Colinz Labs, while the rest, including Desh Rakshak, have Below Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 415.29%, while the lowest is Vineet Laborator at -49.62%, indicating that Desh Rakshak significantly outperforms its peers. Additionally, Phaarmasia, Zenith Health, Colinz Labs, and Parmax Pharma all have negative six-month returns.

Who are in the management team of Desh Rakshak?

As of March 2022, the management team of Desh Rakshak includes Tosh Kumar Jain (Chairman & Managing Director), Monika Jain and Arihant Kumar Jain (Whole-time Directors), Mohit Kumar (Independent Director), Sohini Bansal (Company Secretary & Compliance Officer), and Shruti Gupta (Additional Director). Each member contributes to the company's governance and operations.

As of March 2022, the management team of Desh Rakshak includes the following individuals:<BR><BR>1. Tosh Kumar Jain - Chairman & Managing Director<BR>2. Monika Jain - Whole-time Director<BR>3. Arihant Kumar Jain - Whole-time Director<BR>4. Mohit Kumar - Independent Director<BR>5. Sohini Bansal - Company Secretary & Compliance Officer<BR>6. Shruti Gupta - Additional Director<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

Who are the top shareholders of the Desh Rakshak?

The top shareholders of Desh Rakshak include promoters, with Tosh Kumar Jain holding 28.2% of the shares, and individual investors owning 35.58%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Desh Rakshak primarily include the promoters, with Tosh Kumar Jain holding the highest stake at 28.2%. Additionally, individual investors collectively own 35.58% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company, and there are no pledged promoter holdings.

How big is Desh Rakshak?

As of 24th July, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 31.00 Cr, with recent Net Sales of 8.54 Cr and a Net Profit of 0.72 Cr. The company's Shareholder's Funds are 9.48 Cr and Total Assets amount to 16.32 Cr.

As of 24th July, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 8.54 Cr and a Net Profit of 0.72 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 9.48 Cr and Total Assets of 16.32 Cr.

Are Desh Rakshak latest results good or bad?

Desh Rakshak Aushdhalaya's latest results show strong year-on-year growth in net sales and a slight increase in profit after tax, but recent quarterly performance reveals significant declines in both net sales and net profit, indicating short-term challenges. Overall, the results are mixed.

Desh Rakshak Aushdhalaya's latest results present a mixed picture. On the positive side, the company has achieved significant year-on-year growth in net sales, reporting Rs 5.69 crore for the latest six months, which is an impressive increase of 59.38%. Additionally, the profit after tax (PAT) for the nine-month period has reached Rs 0.58 crore, slightly surpassing the previous year's figure of Rs 0.53 crore.<BR><BR>However, there are notable challenges as well. The quarterly results for June 2025 show a substantial decline in net sales and net profit compared to the previous quarter, with net sales dropping by 70.39% and net profit decreasing by 72.22%. Furthermore, the operating profit before depreciation, interest, and taxes (PBDIT) has also fallen to Rs 0.25 crore, marking the lowest level in the last five quarters.<BR><BR>In summary, while Desh Rakshak has demonstrated strong sales growth and improved profitability over a longer timeframe, the recent quarterly performance indicates significant short-term challenges that the company needs to address.

When is the next results date for Desh Rakshak?

Desh Rakshak will declare its results on 14 November 2025.

Desh Rakshak will declare its results on 14 November 2025.

How has been the historical performance of Desh Rakshak?

Desh Rakshak's historical performance shows a mixed trend, with net sales increasing slightly to 6.27 Cr in Mar'25, stable operating profit, and improved profits before and after tax. Despite rising total liabilities, the company has demonstrated resilience with gradual improvements in profitability and sales.

Answer:<BR>The historical performance of Desh Rakshak shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Desh Rakshak's net sales have shown a slight increase from 6.01 Cr in Mar'24 to 6.27 Cr in Mar'25, following a peak of 6.60 Cr in Mar'21. The total operating income also reflects this trend, reaching 6.27 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 4.73 Cr in Mar'24 to 5.02 Cr in Mar'25. Operating profit (PBDIT) has remained relatively stable, with a slight decrease from 1.30 Cr in Mar'24 to 1.28 Cr in Mar'25. Profit before tax improved from 0.51 Cr in Mar'24 to 0.56 Cr in Mar'25, while profit after tax rose from 0.43 Cr to 0.48 Cr in the same period. The earnings per share (EPS) increased from 0.97 in Mar'24 to 1.08 in Mar'25. On the balance sheet, total liabilities increased from 15.74 Cr in Mar'23 to 16.32 Cr in Mar'24, with total assets also rising to 16.32 Cr. The cash flow from operating activities showed a positive change, with 1.00 Cr reported in Mar'24, while cash flow from investing activities remained negative at -1.00 Cr in Mar'22 and Mar'21. Overall, Desh Rakshak has demonstrated resilience in its financial performance, with gradual improvements in profitability and sales despite fluctuations in expenses and liabilities.

Should I buy, sell or hold Desh Rakshak?

Is Desh Rakshak overvalued or undervalued?

As of November 21, 2025, Desh Rakshak is fairly valued with a PE ratio of 37.17 and an EV to EBITDA of 14.92, showing strong performance compared to peers like Sun Pharma and Cipla, despite recent stock volatility and a YTD return of 159.81%.

As of 21 November 2025, Desh Rakshak's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 37.17, an EV to EBITDA of 14.92, and a Price to Book Value of 1.90. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla stands out as attractive with a PE ratio of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Despite the recent volatility in its stock price, which has seen a significant YTD return of 159.81% compared to the Sensex's 9.08%, the company's valuation metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. Overall, Desh Rakshak appears to be fairly valued in the current market environment.

Which are the latest news on Desh Rakshak?

Why is Desh Rakshak falling/rising?

As of 03-Dec, the stock price of Desh Rakshak Aushdhalaya Ltd is at 37.00, showing no change from the previous session. Despite strong long-term returns, the stock faces stagnation due to mixed short-term performance, declining promoter holding, and weak fundamental metrics.

As of 03-Dec, the stock price of Desh Rakshak Aushdhalaya Ltd is currently at 37.00, with no change from the previous trading session. The stock has shown mixed performance over different periods. In the last week, it has remained flat with a 0.00% change, while over the past month, it has declined by 6.42%. However, the stock has performed exceptionally well year-to-date, with a return of 123.30%, and a significant increase of 146.01% over the past year.<BR><BR>Despite these positive long-term returns, there are several factors contributing to the stock's current stagnation and potential decline. The stock underperformed its sector today by 0.55%, indicating weaker performance relative to its peers. Additionally, the stock has experienced erratic trading, having not traded on one day out of the last 20 days, which may affect investor confidence.<BR><BR>The moving averages indicate that while the stock is above the 200-day moving average, it is below the shorter-term moving averages (5-day, 20-day, 50-day, and 100-day), suggesting a potential downward trend in the short term. Furthermore, the decrease in promoter holding to 50.07% this quarter raises concerns about insider confidence in the company's future prospects.<BR><BR>On the negative side, the company exhibits weak long-term fundamental strength, with an average Return on Capital Employed (ROCE) of 6.89% and poor growth metrics, such as a net sales growth rate of only 7.12% over the last five years. The company's ability to service its debt is also weak, as indicated by a poor EBIT to Interest ratio of 0.91. These factors, combined with flat results reported in the latest quarter, contribute to a cautious outlook for the stock, leading to its current price stagnation.